Currently, CAR T cell therapies have shown significant success in treating certain types of blood cancers, particularly relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL). Research is ongoing to expand their application to other types of cancers, including solid tumors.